Bimatoprost

Generic Name: Bimatoprost

Brand Names: Durysta, Latisse, Lumigan

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₇NO_₄

CAS Number: 155206-00-1

Unique Ingredient Identifier: QXS94885MZ

Background: Bimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as ocular hypertension and glaucoma. Bimatoprost is also used to treat eyelash hypotrichosis, or sparse eyelash growth. It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug.

Indication: Bimatoprost is used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

These patients must be intolerant to other intraocular pressure lowering medications or inadequately responsive to other treatments.

Bimatoprost is also indicated to treat eyelash hypotrichosis.

Associated Conditions: Hypotrichosis of the eyelashes, Increased Intra Ocular Pressure (IOP)

Clinical Trials

Comparison of Different Drugs on Ocular Surface Disease in Glaucoma Patients: a Prospective Randomised Study

Conditions: Glaucoma; Ocular Disorders (I.E. Caused by Ocular Disorders)

Interventions: Drug: Lumigan PF; Xalatan

First Posted Date: 2021-05-21

Last Posted Date: 2021-05-21

Lead Sponsor: National Taiwan University Hospital

Target Recruit Count: 300

Registration Number: NCT04896125

Locations: 🇨🇳
National Taiwan University Hospital, Taipei City, Taiwan

Study of LL-BMT1 in Patients With Elevated Intraocular Pressure

Phase 2

Completed

Conditions: Primary Open Angle Glaucoma
Ocular Hypertension

Interventions: Drug: LL-BMT1

First Posted Date: 2021-02-10

Last Posted Date: 2022-06-08

Lead Sponsor: MediPrint Ophthalmics, Inc.

Target Recruit Count: 5

Registration Number: NCT04747808

Locations: 🇺🇸
Eye Research Foundatoin, Newport Beach, California, United States

Effect of Microneedling, Bimatoprost and Excimer in Vitiligo Treatment

Early Phase 1

Completed

Conditions: Vitiligo

Interventions: Device: Excimer laser
Drug: Bimatoprost
Device: Microneedling with a dermaroller

First Posted Date: 2021-02-04

Last Posted Date: 2022-08-05

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 4

Registration Number: NCT04738149

Locations: 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States

A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Open-Angle Glaucoma
Ocular Hypertension

Interventions: Drug: Bimatoprost SR
Drug: LUMIGAN

First Posted Date: 2020-02-26

Last Posted Date: 2023-06-08

Lead Sponsor: AbbVie

Target Recruit Count: 37

Registration Number: NCT04285580

Locations: 🇺🇸
Coastal Research Associates /ID# 232798, Roswell, Georgia, United States
🇺🇸
Scott and Christie and Associates /ID# 232747, Cranberry Township, Pennsylvania, United States
🇺🇸
The Eye Research Foundation /ID# 232694, Newport Beach, California, United States

and more 3 locations

A Comparative Study of SPARC's SDP-133 Once Daily and Lumigan in Subjects With Open Angle Glaucoma or Ocular Hypertension

Phase 3

Withdrawn

Conditions: Open Angle Glaucoma
Ocular Hypertension

Interventions: Drug: SDP-133
Drug: Lumigan

First Posted Date: 2019-04-25

Last Posted Date: 2021-11-19

Lead Sponsor: Sun Pharmaceutical Industries Limited

Registration Number: NCT03927443

Long-term Safety and Efficacy Extension Trial of Bimatoprost SR

Phase 3

Conditions: Ocular Hypertension
Open-Angle Glaucoma

Interventions: Drug: Bimatoprost SR
Other: Standard of Care

First Posted Date: 2019-03-27

Last Posted Date: 2024-02-13

Lead Sponsor: AbbVie

Target Recruit Count: 600

Registration Number: NCT03891446

Locations: 🇺🇸
Lakeside Vision Center /ID# 240204, Irvine, California, United States
🇺🇸
The Eye Research Foundation /ID# 240186, Newport Beach, California, United States
🇺🇸
Wolstan & Goldberg Eye Associates /ID# 240221, Torrance, California, United States

and more 121 locations

Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

Phase 3

Active, not recruiting

Conditions: Open-Angle Glaucoma
Ocular Hypertension

Interventions: Drug: Bimatoprost (SR)

First Posted Date: 2019-02-22

Last Posted Date: 2024-02-13

Lead Sponsor: AbbVie

Target Recruit Count: 515

Registration Number: NCT03850782

Locations: 🇺🇸
Fraser Eye Center /ID# 235790, Fraser, Michigan, United States
🇺🇸
AMA Eyes Research Institute /ID# 235542, Marysville, Ohio, United States
🇧🇬
MHAT Hadzhi Dimitar /ID# 238248, Sliven, Bulgaria

and more 105 locations